Prostate Specific Antigen Half-Time and Prostate Specific Antigen Doubling Time as Predictors of Response to Androgen Deprivation Therapy for Metastatic Prostate Cancer-Reference-Cited by-同舟云学术

Prostate Specific Antigen Half-Time and Prostate Specific Antigen Doubling Time as Predictors of Response to Androgen Deprivation Therapy for Metastatic Prostate Cancer

Published:2009-06 Issue:6 Volume:181 Page:2520-2525
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Park Yong Hyun¹,Hwang In Sik¹,Jeong Chang Wook¹,Kim Hyeon Hoe¹,Lee Sang Eun¹,Kwak Cheol¹

Affiliation:

1. Department of Urology, Seoul National University Hospital, Seoul, Korea

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference20 articles.

1. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

2. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004

3. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration;Smaletz;J Clin Oncol,2002

4. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer;Halabi;J Clin Oncol,2003

5. Studies on prostatic cancer;Huggins;CA Cancer J Clin,1972

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer;BMC Research Notes;2021-06-03

2. Terapia de privación de andrógenos en pacientes con enfermedad localizada: comparación de las opciones de tratamiento y tiempo hasta la resistencia a la castración. Resultados del Registro Español de Cáncer de Próstata;Actas Urológicas Españolas;2020-04

3. Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry;Actas Urológicas Españolas (English Edition);2020-04

4. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium;Urologic Oncology: Seminars and Original Investigations;2020-01

5. Prognostic significance of early changes in serum biomarker levels in patients with newly diagnosed metastatic prostate cancer;Scientific Reports;2019-08-19